Innate Immunotherapeutics Attracts Strong US Interest
Innate Immunotherapeutics (IIL: $1.59) has seen its share price increase by 89% over the last five weeks, giving the company a market capitalisation of $353 million. The reason has been the heightened profile of the stock in the US (and as a result in Australia) through coverage in the New York Times and other news groups which have discussed interest in the stock from senior Republican politicians in the US. Buying of the stock by US investors has been facilitated through the stock trading on the OTC market in the US.
For further information please download PDF attached:
Download this document